↓ Skip to main content

Dove Medical Press

Article Metrics

What is this page? Embed badge

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not…

Overview of attention for article published in OncoTargets and therapy, July 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
22 Mendeley
Summary Facebook Dimensions citations
Title
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation
Published in
OncoTargets and therapy, July 2013
DOI 10.2147/ott.s45906
Pubmed ID
23836994
Authors

Tamer El-Nahas, Yasser Kader, Le Chevalier, Amr Sakr

Abstract

The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of efficacy and toxicity profile, in Egyptian patients.

View on publisher site

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 9%
Unknown 20 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 23%
Student > Ph. D. Student 3 14%
Other 2 9%
Lecturer 1 5%
Student > Doctoral Student 1 5%
Other 4 18%
Unknown 6 27%
Readers by discipline Count As %
Medicine and Dentistry 13 59%
Biochemistry, Genetics and Molecular Biology 2 9%
Neuroscience 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Unknown 5 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 July 2013.
All research outputs
#20,195,877
of 22,713,403 outputs
Outputs from OncoTargets and therapy
#1,964
of 2,927 outputs
Outputs of similar age
#170,676
of 194,642 outputs
Outputs of similar age from OncoTargets and therapy
#36
of 42 outputs
Altmetric has tracked 22,713,403 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,927 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,642 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.

This page is hosted by Altmetric on behalf of Dove Medical Press.